eli lilly glp 1 oral Lilly's New GLP-1 Orforglipron Beats Semaglutide In Diabetes Trials; FDA Filing Near Eli Lilly's Orforglipron: A Potential

Does semaglutide make COVID-19 worse or increase hospitalization risk

This collaboration not only provides Hansoh Pharmaceutical with an upfront payment of $112 million but also qualifies it for up to $1.9 billion in milestone payments based on the candidate drug's development, registration, approval, and commercialization progress

AOD-9604 has substantial Phase 1, 2, and IIb research from Metabolic Pharmaceuticals' development program

Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Mller MN, et al

The accelerated approval for Eisai and Biogens Leqembi (lecanemab) was converted to a full approval based on results from the confirmatory Clarity-AD trial, which the FDA said in its statement verified the drugs benefit